Ellagic Acid Mitigates Hepato-renal Toxicity Induced by Tacrolimus in Wistar Rats
Shiraz E-Medical Journal · 31.03.2026 · 27 (3)
DOI: 10.5812/semj-167211 ↗Kurz gefasst
Fachartikel in der Zeitschrift Shiraz E-Medical Journal, online erschienen am 31.03.2026. Verfasst von Mohammad Amin Behmanesh und 5 weiteren Autor:innen. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Tacrolimus is commonly prescribed to prevent transplant rejection and manage autoimmune disorders; however, it can cause severe nephrotoxicity and hepatotoxicity. Previous research has highlighted the protective role of ellagic acid (EA) against tacrolimus-induced toxicity.
Objectives
This study aimed to evaluate the protective effects of EA against tacrolimus-induced hepatorenal toxicity in Wistar rats.
Methods
In this experimental study, 24 male Wistar rats (200 ± 20 g, 8 weeks old) were randomly assigned to four groups (n = 6 each): the control group received intraperitoneal normal saline once daily; the tacrolimus group received tacrolimus 1 mg/kg/day by intraperitoneal injection; the tacrolimus + EA group received tacrolimus plus oral EA 50 mg/kg/day; and the EA group received oral EA 50 mg/kg/day. After 28 days, serum levels of ALT, AST, ALP, BUN, and creatinine were measured, along with oxidative stress indicators, including malondialdehyde (MDA), total antioxidant capacity (TAC), thiol proteins (GSH), and 8-hydroxy-2′-deoxyguanosine (8-OHdG). Histopathological analyses of liver and kidney tissues were also performed. Group comparisons were conducted using one-way ANOVA, Welch ANOVA, or the Kruskal-Wallis test, as appropriate, followed by post hoc corrections for multiple comparisons. Statistical significance was set at P < 0.05.
Results
Tacrolimus administration induced significant hepatorenal toxicity and oxidative stress compared with the control group, as evidenced by marked increases in serum AST (153.50 ± 13.35 vs. 83.50 ± 1.78 U/L, P = 0.006), creatinine (1.31 ± 0.04 vs. 0.42 ± 0.01 mg/dL, P = 0.002), and MDA (22.26 ± 1.05 vs. 10.30 ± 0.29 nmol/mL, P < 0.001). Co-treatment with EA significantly attenuated tacrolimus-induced oxidative stress, reducing MDA to 15.67 ± 0.73 (P = 0.001) and restoring GSH to 3.96 ± 0.31 µmol/L (P = 0.007), compared with the tacrolimus group.
Conclusions
Ellagic acid exerts protective effects against tacrolimus-induced hepatorenal toxicity by reducing lipid peroxidation and enhancing antioxidant defenses, suggesting its potential as an adjuvant therapy for patients receiving tacrolimus.
Zitieren
APA
Behmanesh, M. A., Janati, S., Khanifar, M., Masoudipour, F., Pourmotahari, F., & Poormoosavi, S. M. (2026). Ellagic Acid Mitigates Hepato-renal Toxicity Induced by Tacrolimus in Wistar Rats. Shiraz E-Medical Journal, 27(3). https://doi.org/10.5812/semj-167211
Vancouver
Behmanesh MA, Janati S, Khanifar M, Masoudipour F, Pourmotahari F, Poormoosavi SM. Ellagic Acid Mitigates Hepato-renal Toxicity Induced by Tacrolimus in Wistar Rats. Shiraz E-Medical Journal. 2026;27(3). doi:10.5812/semj-167211
BibTeX
@article{Behmanesh2026,
author = {Behmanesh, Mohammad Amin and Janati, Sima and Khanifar, Mohammad and Masoudipour, Fardis and Pourmotahari, Fatemeh and Poormoosavi, Seyedeh Mahsa},
title = {Ellagic Acid Mitigates Hepato-renal Toxicity Induced by Tacrolimus in Wistar Rats},
journal = {Shiraz E-Medical Journal},
year = {2026},
volume = {27},
number = {3},
doi = {10.5812/semj-167211}
}
EUVIMED